Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 04/01/2025 at 22:15, 1 year 2 months ago

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announces the closing of a private placement, issuing convertible promissory notes and unregistered warrants to selected investors, with gross proceeds of approximately $3.448 million

Private Placement Warrants Fundraising Jaguar Health Convertible Notes
BRIEF

published on 03/31/2025 at 14:05, 1 year 2 months ago

Jaguar Health affiche une croissance de son chiffre d'affaires de 20 % en 2024

Résultats Financiers Jaguar Health Produits Sur Ordonnance Réunion De La FDA Croissance Du Chiffre D'affaires En 2024
BRIEF

published on 03/31/2025 at 14:05, 1 year 2 months ago

Jaguar Health Shows 20% Revenue Growth in 2024

Financial Results Jaguar Health Prescription Products FDA Meeting 2024 Revenue Growth
PRESS RELEASE

published on 03/31/2025 at 14:00, 1 year 2 months ago

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Jaguar Health, Inc. reports a 20% increase in total net revenue for 2024, reaching $11.7 million. Expecting first results in Q2 2025 for crofelemer trials. FDA meeting scheduled for Phase 3 OnTarget trial

Financial Results Jaguar Health Net Revenue FDA Meeting POC Trials
BRIEF

published on 03/28/2025 at 14:05, 1 year 2 months ago

Jaguar Health souligne son soutien vétérinaire à Canalevia-CA1

Canalevia-CA1 Approbation De La FDA Oncologie Vétérinaire Chimiothérapie Canine Traitement Non Antimicrobien
BRIEF

published on 03/28/2025 at 14:05, 1 year 2 months ago

Jaguar Health Highlights Veterinary Support for Canalevia-CA1

FDA Approval Canalevia-CA1 Veterinary Oncology Dog Chemotherapy Non-Antimicrobial Treatment
PRESS RELEASE

published on 03/28/2025 at 14:00, 1 year 2 months ago

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Jaguar Health's Canalevia-CA1 receives FDA approval for chemotherapy-induced diarrhea in dogs, addressing a critical unmet need in veterinary oncology

FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea Veterinary Oncology
BRIEF

published on 03/27/2025 at 13:35, 1 year 2 months ago

Jaguar Health obtient une réunion avec la FDA pour discuter des résultats de l'essai Crofelemer sur le cancer du sein

Crofelemer Jaguar Health Cancer Du Sein Réunion De La FDA Étude OnTarget
BRIEF

published on 03/27/2025 at 13:35, 1 year 2 months ago

Jaguar Health Secures FDA Meeting to Discuss Crofelemer Results in Breast Cancer Trial

Crofelemer Jaguar Health Breast Cancer FDA Meeting OnTarget Study
PRESS RELEASE

published on 03/27/2025 at 13:30, 1 year 2 months ago

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Napo Pharmaceuticals presents statistically significant responder analysis results for crofelemer in breast cancer patients at San Antonio Breast Cancer Symposium and MASCC, FDA Type C Meeting scheduled for 2025

Napo Pharmaceuticals Crofelemer Breast Cancer FDA Meeting Responder Analysis

Published on 06/27/2026 at 01:40, 1 hour ago

Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 2 hours 40 minutes ago

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 3 hours 40 minutes ago

Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 3 hours 50 minutes ago

Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 4 hours 25 minutes ago

Revive Therapeutics Announces Proposed Private Placement

View all ACCESSWIRE

Published on 06/27/2026 at 00:05, 2 hours 34 minutes ago

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 2 hours 35 minutes ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 3 hours 4 minutes ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 3 hours 4 minutes ago

EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 3 hours 12 minutes ago

EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE

View all EQS

Published on 06/26/2026 at 17:45, 8 hours 55 minutes ago

Combined General Meeting, June 25, 2026
Published on 06/26/2026 at 17:45, 8 hours 55 minutes ago

Assemblée générale mixte du 25 juin 2026
Published on 06/26/2026 at 17:45, 8 hours 55 minutes ago

Descriptif du programme de rachat d'actions
Published on 06/26/2026 at 14:44, 11 hours 55 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 11 hours 55 minutes ago

Information Safran

View all LES ECHOS COMFI WIRE

News